Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab plus R-CHOP in ctDNA high-risk untreated diffuse large B-cell lymphoma
2021-001647-28Phase 2Active
- Sponsor
- Roche
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab, rituximab, cyclophosphamide, doxorubicin, vincristine and 2 more in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Primary endpoint: End-of-treatment complete response rate. Started Aug 2021; status: active.
02
Drugs
glofitamabrituximabcyclophosphamidedoxorubicinvincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2021-001647-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001647-28.